INSM Insmed announces positive 12-month data from the ongoing open-label extension study of treprostinil palmitil inhalation powder (tpip) i
INSM Insmed announces positive 12-month data from the ongoing open-label extension study of treprostinil palmitil inhalation powder (tpip) in patients with pulmonary arterial hypertension
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.